Men's Health News

RSS

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

New results from a phase II clinical trial of the prostate cancer drug abiraterone suggest that it may help men with advanced disease who have tried standard treatments.

17 Feb 2010

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

Calypso Medical Technologies, Inc., a developer of targeting technology used for accurate, precise real-time tracking of tumor targets, today announced the online publication of a clinical study in Urology (The GOLD JOURNAL). The prospective, multi-site study, entitled, “Assessing the Impact of Margin Reduction (AIM),” is the first outcomes-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.”

17 Feb 2010

'Fertility chip' to accurately count spermatozoa in sperm

A new 'fertility chip', developed by researchers at the University of Twente's MESA+ Institute for Nanotechnology, can accurately count spermatozoa in sperm. This is an important step towards the development of a compact device for reliable 'pre-scanning' of male fertility. The researchers are publishing the invention of the chip in the scientific journal Lab on a Chip.

16 Feb 2010

HIV transmission among male partners: CFAR scientists discover origin of strains

A team of scientists, led by a virologist from the University of California, San Diego's Center for AID Research (CFAR), has discovered the origin of strains of human immunodeficiency virus (HIV) among men who have sex with men. The study, which may be important in developing prevention strategies for HIV, will appear in Science Translational Medicine on February 10, 2010.

12 Feb 2010

Top ten myths about sex

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released ten of the top myths surrounding sex. From which gender spends the most time fantasizing to whether size really matters, the list covers some of the common misconceptions about time spent between the sheets.

10 Feb 2010

New Success Prime IVF Program launched

Reproductive Partners Medical Group, Inc. announces the launch of the Success Prime IVF Program, an IVF money back guarantee for best-case patients.

10 Feb 2010

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

10 Feb 2010

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute.

9 Feb 2010

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.

9 Feb 2010

Repros Therapeutics submits Androxal revised indication statement to the FDA

Repros Therapeutics Inc. today announced that the Company, as requested by the FDA during the Type C meeting held on January 25, 2010, has sent a revised indication statement to the FDA’s Division of Reproductive and Urologic Products for the use of Androxal® in the treatment of men wishing to preserve fertility while being treated for their hypogonadal state.

8 Feb 2010

Non-invasive MR Spectroscopy to determine ability to be fathers

Men with no sperm in their ejaculate—a condition known as azoospermia—may no longer need invasive procedures to determine if they have sperm in their testes according to a new study published in Human Reproduction.

5 Feb 2010

Ipsen launches Decapeptyl LP 22.5 mg in France

Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.

4 Feb 2010

Older male Italian immigrants more prone to depression

Older male Italian immigrants are almost twice as likely to suffer from depression as their Australian-born counterparts, researchers from the University of Sydney's School of Public Health have found.

3 Feb 2010

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Repros Therapeutics Inc. today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial.

3 Feb 2010

Men welcome male contraceptive pill currently undergoing trials

Would you trust men to take a 'male pill'? That's the question posed to 380 people in North East England by a team from Teesside University which questioned people about the male contraceptive pill currently undergoing trials.

28 Jan 2010

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it is discontinuing development of ozarelix in benign prostatic hypertrophy (BPH).

27 Jan 2010

Prostate cancer: Surgery in county hospitals, radiation or hormone therapy in private facilities

Researchers at Moores Cancer Center at the University of California, San Diego and colleagues have found that prostate cancer treatments varied significantly between county hospitals and private providers. Patients treated in county hospitals are more likely to undergo surgery while patients treated in private facilities tend to receive radiation or hormone therapy. These findings were published online by the journal Cancer on January 25.

25 Jan 2010

Smoking and high blood pressure increase risk of abdominal aortic aneurysm in men over 60

Men ages 65 and older who have ever smoked should have a one-time, say cardiologists at UT Southwestern Medical Center. Men age 60 and older with a family history of abdominal aortic aneurysm should also consider screening. High blood pressure and a history of smoking can increase your chances of having an abdominal aortic aneurysm.

23 Jan 2010

Over 44% of internet Viagra is counterfeit

Research by UK, Swedish and American researchers shows that taking internet drugs can kill and bypassing health systems can leave life-threatening problems undiagnosed. It's estimated that 90% of counterfeit drugs are sold on the internet, 44% of internet Viagra is fake, the global sale of counterfeit drugs will reach $75 billion this year and EU seizures have risen dramatically. Counterfeit drug deaths include men who took fake erectile dysfunction drugs, pregnant women injected with fake iron for anaemia and children who took paracetamol syrup contaminated with antifreeze.

20 Jan 2010

Men's Health News

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer

Calypso real-time tumor tracking system usage during IMRT for prostate cancer reduces rectal/urinary side effects

'Fertility chip' to accurately count spermatozoa in sperm

HIV transmission among male partners: CFAR scientists discover origin of strains

Top ten myths about sex

New Success Prime IVF Program launched

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

U.S. PSA screening efficacy lower than in ERSPC-Rotterdam due to lower testing sensitivity

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Repros Therapeutics submits Androxal revised indication statement to the FDA

Non-invasive MR Spectroscopy to determine ability to be fathers

Ipsen launches Decapeptyl LP 22.5 mg in France

Older male Italian immigrants more prone to depression

Repros Therapeutics receives FDA confirmation for initiating Androxal IND

Men welcome male contraceptive pill currently undergoing trials

Spectrum Pharmaceuticals discontinues the development of ozarelix in BPH

Prostate cancer: Surgery in county hospitals, radiation or hormone therapy in private facilities

Smoking and high blood pressure increase risk of abdominal aortic aneurysm in men over 60

Over 44% of internet Viagra is counterfeit

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News